The global contrast media injectors market size was valued at USD 1.27 billion in 2023 and is projected to grow at a CAGR of 7.50% from 2024 to 2030. The contrast media injectors market growth is attributed to the rising prevalence of chronic disorders, technological advancements, and increasing demand for minimally invasive surgical procedures. The rising number of chronic diseases has harnessed the demand for diagnostic imaging tests that use conventional imaging methods such as X-rays and ultrasounds, along with advanced imaging techniques such as CT scans and MRIs. The ability of these tests to diagnose diseases and help to decide on surgeries/treatments in interventional procedures, as well as their use for perioperative imaging before surgeries, is likely to increase the number of contrast media procedures. Thus, the rising prevalence of long-term diseases and complex co-morbidities are major factors propelling market growth.
Moreover, rapid advancements in technology, increased spending on healthcare, and enhancements in patient care quality are leading to the worldwide rise in the demand for minimally invasive surgical procedures. Contrast media injectors are invaluable tools for surgeons. They help them precisely administer contrast agents, thereby minimizing human errors and enhancing the precision and efficiency of operations. These products are essential in the fields of intraoperative interventional radiology and interventional cardiology. The presence of sophisticated injection systems for both diagnostic and intraoperative imaging purposes is expected to drive their increased adoption.
The COVID-19 pandemic affected the contrast media injectors market. Many radiology departments saw a rapid dip in imaging case volume during the pandemic, resulting in a slump in demand for contrast media injectors. However, post-pandemic, organizations are gaining knowledge in their end-to-end supply chains to reduce product prices and improve the quality and services associated with contrast media injectors. Such operational ideas help organizations save money by eliminating third-party expenses, generating lucrative market growth prospects.
The key advantages offered by minimally invasive surgeries (MIS) include faster recovery, smaller incisions, lower risk of infections, minimal scarring, shorter hospital stays and reduced loss of blood during the procedure. These benefits are anticipated to boost the market during the forecast period. Additionally, minimally invasive procedures conducted with contrast media injectors provide real-time imaging and high quality, for surgical or diagnostic procedures, which can create significant opportunities for the surgeons to perform the surgical procedures in the appropriate area, augmenting the overall market. Moreover, a growing number of approvals for contrast media injectors by regulatory bodies, such as the U.S. FDA and the EU, are predicted to contribute to the market growth.
The contrast media injectors market is experiencing a significant degree of innovation driven by advancements in imaging techniques. Many modern injectors are now equipped with IT-enabled solutions that facilitate data management and dosage monitoring. Moreover, strategic collaborations between major players in the industry are fostering innovation through shared research and development efforts. For instance, partnerships like that between Bayer AG and Google Cloud aim to develop AI solutions that enhance the functionality of contrast media injectors.
The sector is witnessing a fair number of mergers and acquisitions conducted by various major entities. This trend is attributed to multiple reasons, such as the aim to secure a competitive edge within the sector and the necessity to consolidate positions within a rapidly expanding market. Moreover, the entities in the market are entering into collaborations and partnerships to broaden their range of products, driven by the fast progress in imaging and injector technologies.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent approval processes for contrast media injectors. These processes require extensive clinical trials and data demonstrating the safety and effectiveness of new devices before they can be marketed.
Key players are adopting the strategy of increasing production capacity and expanding their market reach to improve the availability of their products and services in diverse geographic areas. Leading manufacturers are making robust investments in the development of high-end systems to cater to their customer's needs. These companies launch advanced systems with high accuracy, efficiency, and reliability.
The market is poised for substantial growth across various regions due to increasing disease prevalence, technological advancements, and improved healthcare access. Government initiatives aimed at enhancing healthcare services further support market expansion.
The injector systems held the highest revenue share in 2023. Contrast agents are delivered into the patient's bloodstream during CT, MRI, and angiogram imaging procedures, allowing for improved visualization of the contrast of fluids or structures within the body. CT injector systems, MRI injector systems, and cardiovascular/angiography injector systems are all examples of contrast media injector systems. The CT injector systems segment accounts for the largest revenue share in the contrast media injectors market. This can be attributed to their widespread use in the detection and treatment of vascular disease, cancer, orthopedic injuries, and disorders. Moreover, technological advancements and the launch of new products are expected to propel market growth further.
The consumables segment is expected to grow at the highest CAGR of 8.43% during the forecast period. The increased need for consumables to ensure safety and hygienic conditions during diagnostic procedures contributes to the segment growth. Additionally, the recurring purchases of these consumables for radiology, interventional cardiology, and interventional radiology are likely to boost market growth. Additionally, factors such as higher adoption of contrast media injector consumables, greater availability, and the rising prevalence of chronic diseases worldwide are expected to spur segment growth.
In 2023, the single-head injectors category led the market by capturing the largest revenue, accounting for 43.60%. Known for their use in angiography, CT, and MRI procedures, single-head injectors are favored due to their straightforward mechanism involving a single syringe to administer contrast media. Primarily used in angiography, these injectors differ from their dual-head counterparts, which employ two syringes and are often used in CT systems. Their widespread application, coupled with a lower average selling price, makes single-head injectors particularly appealing to customers in developing countries such as China, India, and Brazil, where financial considerations play a significant role in purchasing decisions, thereby fueling market expansion.
The syringeless injectors segment is expected to grow at the highest CAGR of 8.71% during the forecast period. Syringeless power injectors have become popular to cut down on contrast media waste. Due to the reduced cost and improved performance of syringeless injectors, patients can save approximately $8 per treatment. Major manufacturers are actively working on introducing and advancing syringeless injectors, anticipating a significant impact on the market.
The contrast media injectors market is analyzed for radiology, interventional radiology, and interventional cardiology. In 2023, the radiology segment dominated the market with the largest revenue share of 46.94%. Radiology involves the use of noninvasive imaging technologies such as CT and MRI scans to create comprehensive images. CT scanning involves using X-ray equipment to build a structure of cross-sectional pictures of the body to detect the source of a medical condition, especially in soft tissues. In contrast, MRI technology involves the application of a magnetic field to create images of the inside of a patient’s body. These injectors are used with MRI and CT to identify a broad range of health conditions such as breast cancer, heart diseases, gastrointestinal conditions, fractures, colon cancer, and blood clots. In addition, this segment is projected to grow at a lucrative rate owing to the non-invasive nature of radiology techniques and a rise in the prevalence of chronic diseases.
The interventional cardiology sector is projected to expand at a compound annual growth rate (CAGR) of 8.48% throughout the forecast period. An upsurge in cardiovascular conditions, including stroke, heart attacks, arrhythmias, and disorders of the heart valve, is set to propel the segment's growth. The rising incidences of heart-related ailments are anticipated to bolster the demand for cardiac interventions for both diagnosis and treatment purposes. Furthermore, the segment's growth is likely to be further supported by advancements in technology and an increase in hospital admissions.
The hospital segment dominated the market and accounted for the largest revenue share of 68.37% in 2023. Additionally, this segment is expected to grow at the highest CAGR from 2024 to 2030. This growth can be attributed to the increasing admissions of patients suffering from neurological disorders, cardiovascular diseases, and cancer. Hospitals are the primary users of contrast media injectors, owing to their wide range of applications in radiology, interventional radiology, and interventional cardiology. For instance, according to the 2022 data published by the American Hospital Association, there are 6,120 hospitals in the U.S. Additionally, an increasing focus on the development of healthcare infrastructure in developing countries is expected to propel the market growth.
Furthermore, the diagnostic centers segment is anticipated to grow at a significant CAGR over the forecast period. The rise in the number of private imaging centers, driven by the increased demand for diagnostic imaging and early diagnosis and the shortage of imaging modalities in small and mid-scale hospitals, is a significant factor driving the growth of diagnostic imaging centers.
North America dominated the market and accounted for 38.08% revenue share in 2023 owing to the presence of well-established healthcare facilities and easy availability of advanced technologies. Additionally, the increasing demand for diagnostic procedures in the region is expected to increase the number of inpatient examinations, which is expected to boost market growth.
The contrast media injectors market in the U.S. is expected to grow over the forecast period. The rising prevalence of chronic diseases such as heart disease, cancer, chronic lung disease, stroke, Alzheimer’s disease, diabetes, and chronic kidney disease in the adult population demands well-equipped hospitals and operating rooms. Additionally, the increasing number of hospitals and ambulatory surgery centers in the country, and technological innovations in medical devices contribute to the market growth.
The Europe contrast media injectors market is experiencing significant growth, driven by various factors, including technological advancements, the increasing prevalence of chronic diseases, and a rising demand for diagnostic imaging procedures.
The UK contrast media injectors market is expected to grow over the forecast period. The increasing prevalence of chronic diseases, established healthcare infrastructure, and technological advancements are some of the factors driving market growth.
The contrast media injectors market in Germanyis expected to grow over the forecast period, driven by factors such as advancements in diagnostic imaging technology, the country’s robust healthcare system, presence of key market players, and rising investments in medical devices’ research and development.
France contrast media injectors market is anticipated to grow over the forecast period. This growth is driven by increasing demand for advanced imaging techniques and rising healthcare expenditure.
TheAsia Pacific contrast media injectors marketis anticipated to witness the fastest CAGR of 8.57% from 2024 to 2030 due to the rising prevalence of chronic diseases, growing awareness regarding advanced therapies, and the increasing geriatric population. In addition, rapidly developing economies and anincrease in disposable incomes further drive market growth. Moreover, neurological diseases are strongly associated with aging, and mostly begin in people aged 60 years and older. Thus, there is a high demand for advanced surgical treatment solutions for these diseases, which is expected to propel the demand for advanced contrast media injectors.
The Japan contrast media injectors market is anticipated to grow at a significant CAGR over the forecast period. Continuous advancements in healthcare technology are improving imaging capabilities and patient outcomes. Moreover, the country’s aging population contributes to a higher incidence of age-related illnesses, thereby boosting the need for accurate diagnostic tools like contrast media injectors.
The contrast media injectors market in Chinais expected to grow over the forecast period owing to increasing demand for imaging procedures, technological advancements, and the growing geriatric population.
India contrast media injectors market is anticipated to grow rapidly over the forecast period. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular, and neurological disorders is the key factor boosting market growth. In addition, the country’s rapidly developing economy and anincrease in disposable income further drives market growth.
The contrast media injectors market in the Middle East and Africais projected to grow in the near future. Both governmental and non-governmental organizations are investing in healthcare infrastructure and research initiatives aimed at improving diagnostic capabilities in the MEA region. Such investments facilitate access to advanced medical technologies, including contrast media injectors. Moreover, the growing preference for minimally invasive surgical techniques is another driver for the market growth.
The contrast media injectors market in Saudi Arabiais expected to grow over the forecast period due to the growing healthcare infrastructure, technological advancements, and government initiatives and funding aimed at improving patient outcomes through better diagnostic services.
The UAE contrast media injectors market is anticipated to witness growth over the forecast period due to the increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, and growing investments by key players.
Key players operating in the contrast media injectors market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are playing a key role in propelling the market growth.
The following are the leading companies in the contrast media injectors market. These companies collectively hold the largest market share and dictate industry trends.
In November 2023, Bracco partnered with ulrich medical for syringeless magnetic resonance injectors. This partnership helped Bracco to launch its product in the U.S. market.
In November 2022, GE Healthcare and ulrich medical collaborated to offer multi-dose contrast media injectors in the U.S. This injector delivers iodinated contrast media for CT imaging procedures, reducing procedure setup time and increasing patient throughput.
In November 2022, GE Healthcare announced an investment of USD 80 million to increase contrast media production capacity. By 2025, GE Healthcare aims to manufacture 30 million more doses of contrast media every year, which is anticipated to boost the market's growth in the near future.
In September 2019, Bayer launched the MEDRAD Stellant FLEX computed tomography (CT) injection system with an advanced injector system that drives individualized patient protocols and personalized imaging.
Report Attribute |
Details |
Market size value in 2024 |
USD 1.35 billion |
Revenue forecast in 2030 |
USD 2.08 billion |
Growth rate |
CAGR of 7.50% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, type, application, end-use, region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Country scope |
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
Key companies profiled |
Bayer HealthCare LLC; Bracco Group; Ulrich Medical; Guerbet Group; Medtron AG; Nemoto Kyorindo Co., Ltd.; Hong Kong Medi Co Limited. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global contrast media injectors market report based on product, type, application, end-use, and region.
Product Outlook (Revenue, USD Million, 2018 - 2030)
Injector Systems
CT injector systems
MRI injector systems
Cardiovascular/angiography injector systems
Consumables
Tubing
Syringe
Interventional Radiology
Type Outlook (Revenue, USD Million, 2018 - 2030)
Single-head Injectors
Dual-head Injectors
Syringeless Injectors
Application Outlook (Revenue, USD Million, 2018 - 2030)
Radiology
Interventional Cardiology
Interventional Radiology
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
b. The global contrast media injectors market size was estimated at USD 1.27 billion in 2023 and is expected to reach USD 1.35 billion in 2024.
b. The global contrast media injectors market is expected to grow at a compound annual growth rate of 7.5% from 2024 to 2030 to reach USD 2.08 billion by 2030.
b. CT injector systems dominated the contrast media injectors market in 2023. This is attributable to the rising widespread application of these systems in cancer surgery, neurosurgery, cardiovascular surgery, and spinal procedures.
b. Some key players operating in the contrast media injectors market include Bracco Group; Guerbet Group; Medtron AG; Bayer HealthCare LLC; Ulrich GmbH & Co. KG; Nemoto Kyorindo Co., Ltd.; GE Healthcare; VIVID IMAGING; Sino Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd.
b. Key factors that are driving the contrast media injectors market growth include technological advancements and increasing demand for minimally invasive surgeries.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."